Inhibition of autophagy enhances the cytotoxic effect of PA-MSHA in breast cancer
- Wen-Huan Xu†1, 2, 3, 4,
- Zhe-Bin Liu†1, 2, 3,
- Yi-Feng Hou1, 2, 3,
- Qi Hong1, 2, 3,
- Da-Li Hu5 and
- Zhi-Ming Shao1, 2, 3Email author
© Xu et al.; licensee BioMed Central Ltd. 2014
Received: 23 July 2013
Accepted: 11 March 2014
Published: 21 April 2014
PA-MSHA, a genetically engineered Pseudomonas aeruginosa (PA) strain, is currently under investigation as a new anti-cancer drug. It can induce cell cycle arrest and apoptosis in different human cancer cells, including hormone receptor negative breast cancer cells. However, the underlying mechanism of tumor lethality mediated by PA-MSHA remains to be fully investigated.
The effect of PA-MSHA on human hormone receptor negative breast cancer cells was analyzed by morphological measurement, western blot, cell proliferation assay and mouse xenograft model.
PA-MSHA was found to induce endoplasmic reticulum (ER) stress in breast cancer cell lines through the IRE1 signaling pathway. Inhibiting autophagy potentiated the cytotoxic effect of PA-MSHA while treating breast cancer cell lines. In mouse xenograft model, PA-MSHA produced more pronounced tumor suppression in mice inoculated with IRE1 gene knockdown. MDA-MB-231HM cells.
These findings demonstrated inhibiting autophagy together with PA-MSHA might be a promising therapeutic strategy in treating hormone receptor negative breast cancer cells.
KeywordsPA-MSHA ER stress Autophagy IRE1 Breast cancer
Breast cancer, one of the leading causes of cancer related mortality in women, is a disease with heterogeneous nature. Meanwhile “basal-like” breast cancer, ER and PR negative, is characterized by its aggressive behavior, distinct patterns of metastasis and lack of targeted therapies [1, 2]. PA-MSHA, a genetically engineered Pseudomonas aeruginosa strain, has been successfully used as a protective vaccine  for adjuvant therapy of lymphoma and lung cancer. In recent preclinical studies, cytotoxic effect of PA-MSHA was observed in ER, PR negative breast cancer cells but not in ER, PR positive breast cancer cells . The same effect was also exhibited in human hepatocarcinoma cells treated by PA-MSHA . Given the increasing prevalence of PA-MSHA usage on cancer patients, further laboratory investigation are needed to better understand its anticancer mechanism.
Many chemotherapeutic drugs induce cell death via the endoplasmic reticulum (ER) stress mediated apoptotic pathway [6, 7]. ER is composed of membranous tubules and vesicles. It serves cells with a Ca2+ reservoir and facilitates the secretion of properly folded proteins [8, 9]. Disturbances in normal ER process lead to accumulation of unfolded proteins and trigger the unfolded protein response (UPR), which compensate the damage by reducing global protein synthesis and elicit autophagy, an alternate degradation system [10–12]. IRE1 and PERK/eIF2α are reported to be involved in the induction of autophagy upon ER stress.Autophagy can prevent the accumulation of toxic components in cells by sequestering cytoplasmic materials to autophagic vesicles and degrading them in the lysosome and recycling these materials . In many studies, autophagy was induced while cancer cells faced with therapeutic stress, such as chemotherapy, radiotherapy and endocrine therapy .
In present study, we found that autophagy was stimulated in breast cancer cells upon ER stress of PA-MSHA through IRE1 pathway. Inhibition of autophagy promoted apoptosis both in vivo and in vitro. Our results provide molecular evidence that inhibiting autophagy will enhance PA-MSHA induced apoptosis in HR negative breast cancers.
Cell lines and materials
Human breast cancer cell lines MDA-MB-231 and MDA-MB-468 were obtained from the American Type Culture Collection. MDA-MB-231HM cell line was established by subclone selection procedure in our institute. The MDA-MB-231HM cell line has a high potential to metastasize to the lung and its establishment has been described previously . The PA-MSHA used in this study was same as we used in our previous study . Following reagents and primary antibodies were used: anti-LC3 (Cell Signaling Technology, Danvers, MA), anti-GAPDH, anti-caspase3, anti-cleaved-caspase3, anti-CHOP, anti-IRE1-a, anti-ATG5 (Santa Cruz Biotechnology Inc., Santa Cruz, CA); 3-MA and tunicamycin (Sigma-Aldrich, St. Louis, MO, USA). Lipofectamine 2000 reagent was obtained from Invitrogen (Cat. No 11668-019).
Cell lysates were prepared by extracting proteins with lysis buffer. Proteins were separated by sodium dodecyl sulfate polyacrylamidel gel electrophoresis and transferred to PVDF membranes. The membranes were blocked and incubated with primary antibodies. After incubation with peroxidase-conjugated secondary antibodies, the blots were visualized by enhancing chemiluminescence reagents.
Transmission electron microscopy
Transmission electron microscopy was used to determine the effect of PA-MSHA treatment on the ultrastructure of breast cancer cells as described by Watkins and Cullen . Ultra thin sections (65 nm) were examined under a JEM-100CX transmission electron microscope (JEOL, Japan) at × 84,00 or × 15,000 magnification.
Flow cytometry with annexin V-FITC and PI staining
Cells were pretreated with solution containing of 2 mM 3-MA, 10 × 108 cells/ml PA-MSHA, or 3-MA in combination with PA-MSHA for 48 hours. Single-cell suspensions with at least 1 × 106 cells/ml were made. Apoptotic analyses were done by flow cytometry (FCM) as previously described  using a FACScalibur system (Becton Dickinson Biosciences, San Diego, CA). Propidium iodide-negative and annexin V-positive cells were analyzed by quadrant statistics as apoptotic cells.
Cytotoxic effect was evaluated by the Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies Inc., Gaitherbury, MD) assay. Cells were treated with specified concentration of PA-MSHA, 3-MA or 3-MA in combination with PA-MSHA and incubated at 37°C for 12, 24, 36 and 48 hours. Then, 10 μl of CCK-8 was added to every well, and the cells were incubated for an additional 3 hours at 37°C, after which the absorbance at 450 nm was recorded using a 96-well plate reader (Sunrise Microplate Reader, Tecan US, Inc., Charlotte, NC).
Lentiviral-mediated knockdown of IRE1
Short hairpin RNA molecules targeted against human IRE1 gene were designed and synthesized by Sangon Biotech., Shanghai, China. The sequences of shRNAs targeting IRE1 was 5’-CTACTGGATAAACTTGCTTCA-3’. Oligonucleotides were annealed and inserted into digested PLKO.1-puro. Production of the lentiviral particles were carried out according to the manufacturer’s protocol. MDA-MB-231HM and MDA-MB-231HM cells were infected with lentivirus particles containing the shRNA and stable transfectants were selected and cultured in medium containing 3 ng/μl puromycin. The PLKO.1 scramble plasmid was packaged as a negative control. The PLKO.1 puro plasmid, packaging plasmid, pCMV- dR8.91 and envelope VSV-G were purchased from Addgen (Cambridge, MA).
Morphological measurement of apoptosis
The morphological changes of apoptosis were assayed under a fluorescence microscope following staining with Hoechst 33258. Cells were treated with specified concentration of PA-MSHA for 48 h at 37°C, and then stained with 5 mg/L Hoechst 33258 (Sigma, St. Louis, MO) for 30 min at 37°C, visualized under a fluorescence microscope with standard excitation filters. The apoptotic cells were visualized at × 400 magnification.
Animal xenograft model
This study followed the ethical approval of Fudan University Experimental Animal Department for research involving animals. 4-6 weeks old female BALB/c nude mice used in the study were provided by Shanghai Institute of Material Medica, Chinese Academy of Science. 2 × 106 cells/ml MDA-MB-231HM-shCON cells and MDA-MB-231HM-shIRE1 cells suspended in 0.1 ml PBS were implanted into the mammary fat pad of mice. A total of 24 mice were randomized and assigned into four groups in the study. These mice were given 0.1 ml PA-MSHA (2.2 × 1010 cells/ml) s.c treatment every other day. Tumor volume was measured twice per week with calipers and calculated using the formula V (mm3) = 0.52 × ab2 (a = length, b = width). Body weight was recorded twice a week. The mice were killed and autopsied 6 weeks after tumor inoculation. Tumors were dissected and snap frozen for molecular biology analyses.
Statistical analysis was performed using the software of Statistical Package for the Social Sciences (SPSS) Version 15 for Windows (SPSS Inc., Chicago, IL). Student’s t tests were used to determine statistical significance of differences between experimental groups. A P-value of less than 0.05 was considered significant. Graphs were created with Excel software (Microsoft Office for Windows 2003).
PA-MSHA induces ER stress in breast cancer cells
Autophagosome formation is activated upon PA-MSHA induced ER stress
Characteristic punctate fluorescent patterns of EGFP-LC3 in cells treated with PA-MSHA for 24 hours were also observed, indicating the existence of autophagosome  (Figure 2D). Morphometric analysis of the EGFP fluorescence images revealed that the percentage of EGFP-LC3-punctate staining cells was 0.67% and 3.33% of the total cells in the absence and presence of PA-MSHA respectively. The EGFP fluorescence area increased about 4.97-fold after the treatment of PA-MSHA (Figure 2E). These indicated autophagy was activated by PA-MSHA.
The IRE1 signaling pathway is required for activation of PA-MSHA-induced autophagy in breast cancer cells
ER stress was reported to trigger autophagy while facing cell damage stress in many studies [10–12]. IRE1 was involved in the induction of autophagy upon ER stress. Previously, we found elevated expression of CHOP in PA-MSHA treated breast cancer cells. Since CHOP was also reported to be up-regulated by IRE1, we postulated that IRE1 signaling pathway might be required for activation of PA-MSHA-induced autophagy in breast cancer cells. IRE1-shRNA was used to confirm our hypothesis.
Protective effects of autophagy during PA-MSHA-induced ER stress
Tumor suppression induced by PA-MSHA is enhanced by inhibiting autophagy
Previous study showed that inhibiting autophagy in vitro would result in more death in breast cancer cells treated with PA-MSHA. We next assessed whether suppression of autophagy would also potentiate the cytotoxic effects of PA-MSHA in vivo. We divided nude mice in four groups: (a) mice implanted with MDA-MB-231HM-shCON cells treated with vehicle only, (b) mice implanted with MDA-MB-231HM-shCON cells treated with PA-MSHA only, (c) mice implanted with MDA-MB-231HM-shIRE1 cells treated with vehicle only, (d) mice implanted with MDA-MB-231HM-shIRE1 cells and treated with PA-MSHA only. 6 weeks after inoculation, 5 out of 6 mice (83.3%) in the shIRE1 + PA-MSHA group were found with tumors. Rates of grafted tumor in the other 3 groups were 100%. One nude mouse in shCON + PBS group died the day before all the mice were killed.
PA-MSHA , successfully used as a vaccine , has recently been validated to induce cytotoxic effect against human carcinoma cells . PA-MSHA can also inhibit the hormone receptor negative breast cancer cells in a mannose-sensitive manner . However, the direct mechanism for tumor lethality mediated by PA-MSHA remains to be fully characterized.
In this study, we mainly focused on the tumor cytotoxic ability of PA-MSHA on the HR negative breast cancer cells. We found enlarged vacuoles in HR negative breast cancers upon treatment of PA-MSHA. One possible explanation for these vacuoles is the induction of the UPR. UPR is an adaptive process, it can block protein translation and allows cells to compensate for protein accumulation and misfolding in the ER. Elevated GRP78/Bip and CHOP expression, typical evidence of the activation of ER stress-dependent UPR signaling pathway, was also found in HR negative breast cancer cells treated with PA-MSHA.
However, if the damage is too severe and persistent, ER stress will trigger autophagy to avoid cell damage, which may include IRE1/CHOP or PERK/eIF2α pathway. In our study, elevated CHOP and autophagy following PA-MSHA treatment were observed. Knocking down of IRE1 decreased autophagy and enhanced cell death in cells upon PA-MSHA treatment. These results indicated autophagy, induced by IRE1, was a protective agent of ER stress.
In our study, more TUNEL-positive cells was found in PA-MSHA treated MDA-MB-231HM- shIRE1 cells inoculated tumors compared with MDA-MB-231HM- shCON cells inoculated tumors. Furthermore, increased apoptosis was observed after autophagy was compromised in vivo. This was consistent with previous reported studies. One study had demonstrated that autophagy induced by Epirubicin protected breast cancer cells . Another study revealed that autophagy acted as a survival signal in CML cells treated with tyrosine kinase inhibitors (TKIs) and CML cells resistant to TKIs can be abrogated by autophagy inhibitors . Endostatin was also reported to induce autophagy in addition to apoptosis in endothelial cells .
Since inhibiting autophagy can lead to cell death [24, 25], it provides a novel strategy in cancer therapy. The data presented herein suggested that autophagy inhibitors might be useful alliance of PA-MSHA in future clinical trials. In our study, no significant body weight loss was found in shIRE1 inoculated mice. This indicated there might be no additional toxicity using shRNAs as autophagy inhibitors. It will also be interesting to investigate whether other known or novel pharmacological inhibitors of autophagy can enhance the anticancer activity of PA-MSHA. Chloroquine, which has been used safely for decades in patients which malaria prophylaxis, may be a good choice.
To our knowledge, this is the first report showing that PA-MSHA can induce ER stress in hormone receptor negative breast cancer cell lines. The ER stress activated autophagy through IRE1 dependent pathway. Acting as a pro-survival mechanism, autophagy alleviated PA-MSHA induced ER stress and facilitated the development of PA-MSHA-acquired resistance. Our data suggested that blocking autophagy with either genetic or chemical inhibitors may enhance the cytotoxicity induced by PA-MSHA. The alliance of autophagy inhibitors and PA-MSHA might be considered in future clinical trials treating hormone receptor negative breast cancer patients.
Inositol requiring enzyme 1
Unfolded protein response.
This research is supported by grants from the National Natural Science Foundation of China (30971143, 30972936, 81072165, 81001169, 81202080), the Shanghai United Developing Technology Project of Municipal Hospitals (SHDC12010116), the Key Clinical Program of the Ministry of Health (2010–2012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumors. Nature. 2000, 406: 747-752. 10.1038/35021093.View ArticlePubMed
- Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98: 10869-10874. 10.1073/pnas.191367098.PubMed CentralView ArticlePubMed
- Li Z, Hao D, Zhang H, Ren L, Yang Y, Li L, Chai J, Zhou X, Fu L: A clinical study of PA-MSHA vaccine used for adjuvant therapy of lymphoma and lung cancer. Hua Xi Yi Ke Da Xue Xue Bao. 2000, 15: 334-337.
- Liu ZB, Hou YF, Min-Dong Di GH, Wu J, Shen ZZ, Shao ZM: PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem. 2009, 108: 195-206. 10.1002/jcb.22241.View ArticlePubMed
- Cao Z, Shi L, Li Y, Wang J, Wang D, Wang G, Sun B, Mu L, Yang M, Li H: Pseudomonas aeruginosa: mannose sensitive hemagglutinin inhibits the growth of human hepatocarcinoma cells via mannose-mediated apoptosis. Dig Dis Sci. 2009, 54: 2118-2127. 10.1007/s10620-008-0603-5.View ArticlePubMed
- Boyce M, Yuan J: Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ. 2006, 13: 363-373. 10.1038/sj.cdd.4401817.View ArticlePubMed
- Xu C, Bailly-Maitre B, Reed JC: Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest. 2005, 115: 2656-2664. 10.1172/JCI26373.PubMed CentralView ArticlePubMed
- Bernales S, Papa FR, Walter P: Intracellular signaling by the unfolded protein response. Annu Rev Cell Dev Biol. 2006, 22: 487-508. 10.1146/annurev.cellbio.21.122303.120200.View ArticlePubMed
- Momoi T: Conformational diseases and ER stress-mediated cell death: apoptotic cell death and autophagic cell death. Curr Mol Med. 2006, 6: 111-118. 10.2174/156652406775574596.View ArticlePubMed
- Criollo A, Maiuri MC, Tasdemir E, Vitale I, Fiebig AA, Andrews D, Molgó J, Díaz J, Lavandero S, Harper F, Pierron G, di Stefano D, Rizzuto R, Szabadkai G, Kroemer G: Regulation of autophagy by the inositol trisphosphate receptor. Cell Death Differ. 2007, 14: 1029-1039.PubMed
- Ding WX, Ni HM, Gao W, Hou YF, Melan MA, Chen X, Stolz DB, Shao ZM, Yin XM: Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem. 2007, 282: 4702-4710. 10.1074/jbc.M609267200.View ArticlePubMed
- Høyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, Bianchi K, Fehrenbacher N, Elling F, Rizzuto R, Mathiasen IS, Jäättelä M: Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-b, and Bcl-2. Mol Cell. 2007, 25: 193-205. 10.1016/j.molcel.2006.12.009.View ArticlePubMed
- Levine B, Klionsky DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004, 6: 463-477. 10.1016/S1534-5807(04)00099-1.View ArticlePubMed
- Kondo Y, Kanzawa T, Sawaya R, Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005, 5: 726-734. 10.1038/nrc1692.View ArticlePubMed
- Li JY, Ou ZL, Yu SJ, Gu XL, Yang C, Chen AX, Di GH, Shen ZZ, Shao ZM: The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. Breast Cancer Res Treat. 2012, 131: 837-848. 10.1007/s10549-011-1502-6.View ArticlePubMed
- Watkins SC, Cullen MJ: A qualitative and quantitative study of the ultrastructure of regenerating muscle fibres in Duchenne muscular dystrophy and polymyositis. J Neurol Sci. 1987, 82: 181-192. 10.1016/0022-510X(87)90017-7.View ArticlePubMed
- Wang JS, Wang FB, Zhang QG, Shen ZZ, Shao ZM: Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol Cancer Res. 2008, 6: 372-382. 10.1158/1541-7786.MCR-07-0162.View ArticlePubMed
- Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19: 5720-5728. 10.1093/emboj/19.21.5720.PubMed CentralView ArticlePubMed
- Tasdemir E, Galluzzi L, Maiuri MC, Criollo A, Vitale I, Hangen E, Modjtahedi N, Kroemer G: Methods for assessing autophagy and autophagic cell death. Methods Mol Biol. 2008, 445: 29-76. 10.1007/978-1-59745-157-4_3.View ArticlePubMed
- Mu XY: Success in establishing the MSHA-positive Pseudomonas aeruginosa fimbrial strain. Wei Sheng Wu Xue Bao. 1986, 26: 176-179.PubMed
- Sun WL, Chen J, Wang YP, Zheng H: Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy. 2011, 7: 1035-1044. 10.4161/auto.7.9.16521.View ArticlePubMed
- Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B: Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009, 119: 1109-1123. 10.1172/JCI35660.PubMed CentralView ArticlePubMed
- Ramakrishnan S, Nguyen TM, Subramanian IV, Kelekar A: Autophagy and angiogenesis inhibition. Autophagy. 2007, 3: 512-515.View ArticlePubMed
- Harding HP, Calfon M, Urano F, Novoa I, Ron D: Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol. 2002, 18: 575-799. 10.1146/annurev.cellbio.18.011402.160624.View ArticlePubMed
- Qin L, Wang Z, Tao L, Wang Y: ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy. 2010, 6: 239-247. 10.4161/auto.6.2.11062.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/273/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.